Verdence Capital Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 13.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,699 shares of the biopharmaceutical company’s stock after buying an additional 3,261 shares during the period. Verdence Capital Advisors LLC’s holdings in Gilead Sciences were worth $2,238,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. CarsonAllaria Wealth Management Ltd. raised its holdings in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 238 shares in the last quarter. nVerses Capital LLC bought a new stake in Gilead Sciences during the third quarter worth approximately $25,000. Valued Wealth Advisors LLC raised its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. Cedar Wealth Management LLC raised its holdings in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 160 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences during the second quarter worth approximately $33,000. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences Trading Down 1.4 %
Gilead Sciences stock opened at $96.57 on Friday. The company’s fifty day simple moving average is $85.30 and its 200-day simple moving average is $75.03. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.32. The stock has a market cap of $120.22 billion, a P/E ratio of 1,072.94, a P/E/G ratio of 3.19 and a beta of 0.17.
Gilead Sciences Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.19%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.
Insider Activity at Gilead Sciences
In related news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,437 shares of company stock valued at $5,374,825. Insiders own 0.16% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on the company. Truist Financial boosted their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday. Piper Sandler lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Oppenheimer lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $91.50.
Check Out Our Latest Report on GILD
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- What are earnings reports?
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Investing In Automotive Stocks
- MarketBeat Week in Review – 11/4 – 11/8
- Pros And Cons Of Monthly Dividend Stocks
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.